Grant. Thanks,
activities manufacturing VAX-XX accomplishments the and and be submission. get process the update, this remaining to would into IND think necessary program I I review status for helpful application it our enable Before the for to
the following for shared, previously steps. we four VAX-XX As process manufacturing included the
manufacture our we First, carrier. protein eCRM, proprietary
Second, each we for pneumococcal XX in manufacture one VAX-XX. serotypes included polysaccharides, the of
drug of accomplishments eCRM pneumococcal fourth manufacturing process the release testing drug of attached including in XX by drug three the the stages; the to polysaccharides finally, and polysaccharides. conjugated we year. final completed covalently The made the activated towards manufacture generate To-date, XX conjugated a consist GMP first, conjugated carrier each past sized progress to to to protein vials. each XX which both the of successfully and our substances. weight, the the into leaker of linked we’ve XX Third, step in IND is XX discrete XX We��ve resulting activated filing, substances substances, targeted molecular polysaccharides. and filling conjugated key the or a mixing product includes of the significant polysaccharides drug size number carrier the to manufacturer eCRM protein XX polysaccharides And the XX and of are a then of
For source the our our each sized of successfully now of XX activated the of this These the block XX year, manufactured will midst IND. our for of of the drug stability Lonza. with in are at successfully conjugated batches and substance, initial our manufacturing drug Earlier the data conjugated as and the serve we’ve we substances. lead product batches XX each polysaccharides conjugate drug
this of initiated completed of drug year. toxicology toxicology successfully batches in study GLP manufacturing and first the also used the quarter We in the GLP studies, product
Now, the from outstanding the our and and first, of which currently toxicology second, of third, GMP study manufacturing drug we the before substances completion items, we drug include, have stability drug submit data still is submission of resulting and generation GLP and release few IND, product; GMP testing of completion underway; product. that the conjugated a
our guidance on. As VAX-XX the more which IND mentioned, of as result a detail for provide a factors, Grant we’re updating will I submission few
in of of First, a but the the cause cumulative meaningful GMP delays as production campaign. stages production, across issues delay through themselves, the progressed process-related Lonza. only of substances, In XX transitioned manufacturing together these have experienced we have and the some as at drug into resulted taken we to minor we three
While guidance we these these cumulative changes. for of are adjustments and vaccine impact process our development typical has initial underestimated the stage accounted this the modifications, of for
interruption world-class conjugation of Lonza XX substance complete the able at production with has substance many of now have conjugating stages of Lonza, stage, are stage we we substances. noted, encountered drug Ultimately, team drugs before an midst the benefits. I now successfully the As drug working the through were a to we campaign first the manufacturing campaign, such final of the as final the two and progressed of in
commercial However, they with and late clients have stage clinical products. numerous also
The As a the manufacturing conjugate encouraging is and customer of unfortunately have are we due early XX result, news our interrupted our prior Lonza’s resumed campaign towards commitments. conjugated good completing the which data drugs that GMP was working to substances. campaign, manufacturing
Finally, pandemic restrictions operational equipment travel in-person delayed CMO created analytical oversight. of some headwinds, qualification COVID-XX and the the key
slowed. also raw saw chain supply material We
and look issues believe guidance. progress in Fortunately, been the resolved. forward we the for to VAX-XX remaining delivering all, these IND do made current now our have completing substantial we deliverables towards All have
VAX-XP, and potential currently we’re with robustness expanded noted, at in of The of VAX-XP Immunogenicity Data in candidate circulating the of announcing pneumococcal previously strains, invasive strains the also XX PCV disease the demonstrates coverage least platform. XX% of New scalability for technology States. data today new As United our over our breadth our cover
we in rabbits, XX. during Lonza, scale-up like in transfer than demonstrate polysaccharide VAX-XP was process In all pneumococcal compared the the contained to show XX. that also including more and at VAX-XP study different results Prevnar of to those only they serotypes this to Importantly, XX Prevnar fidelity the maintained. least superior those contained in XX Pneumovax serotypes The comparable that to immuneresponses and were conducted
rate VAX-AX, or grave Group of an and are a antibiotic an million the disease series of of year a over can for turning to to these have to million candidate Jeff pharyngitis, in ubiquitous I the develop thought Before on this due a over invasive Strep U.S., CDC The a recommended of to to are pneumococcal the outcomes. deaths an need to throat, to globally. In Group vaccine population. cases disease Strep status disease has rate half other to But the prophylactic significant strep in creates since best-in-class heart not adult of the usage disease only a Jeff the globally increased SV of XX decade. A an A of substantially invasive the significant has update times This rheumatic also A global XXXX. to it disease infections, estimated children, disease, believe first-in-class consequently vaccine for increased We result the VAX-AX VAX-AX estimated it the has increasing need. than want than a resistance. but address touch pathogen. combination diseases. provide the Group of opportunity XX invasive rate over three Strep provide more now per that, which of I'll XXX elderly program of more in childhood also adults adults. With disease past it's invasive traditionally is prevent are There for causing source prescriptions, upon potential doubled antibiotic Prevnar to as the over and update. designed and majority and the when turn address And
